USA flag logo/image

An Official Website of the United States Government

Device to Improve Treatment of Colorectal CA using O2 Dependent Phosphorescence

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R44CA153571
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
PA11-096
Small Business Information
SURGISENSE CORPORATION
5272 River Road Suite 200 Bethesda, MD -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Device to Improve Treatment of Colorectal CA using O2 Dependent Phosphorescence
Agency: HHS
Contract: 2R44CA153571-02
Award Amount: $1,750,986.00
 

Abstract:

DESCRIPTION (provided by applicant): Standard of care for surgical resection of rectal cancer is the performance of low anterior resection (LAR). After removal of the cancerous segment, a surgical stapler is used to restore continuity by creating an anastomosis between the resulting ends of disjointed bowel. Anastomotic leak is one of the most dreaded complications of colorectal surgery due to the morbidity and mortality caused by fecal contamination of the abdominal cavity. Anastomotic leak, after LAR forrectal cancer, has been reported to occur in as many as 14% of patients; three times more frequently than with other bowel resections. The sequela of anastomotic leak can include local abscess formation, debilitating pain, dysfunctional defecation, overwhelming bacterial sepsis, and death. The consequences are so severe that surgeons subjectively opt to divert the fecal stream away from the healing anastomosis to an ostomy; many months later the patient is then subject to an additional operation to restorenormal defecation. While creation of a diverting ostomy can lessen the impact of anastomotic leak, it does not prevent the leak, and poses a high risk for additional complications while significantly compromising the lifestyle of the recovering patient. There is neither a clinically practical method available for predicting which patients will experience an anastomotic leak, nor an objective set of criteria by which a surgeon can select those patients that would benefit from an ostomy. The long term goal ofthe proposed research is to reduce the rate of anastomotic leak and unnecessary ostomy diversion through the creation of an objective, repeatable means by which to screen patients intra-operatively. Patients at low risk will avoid an unnecessary ostomy. Patients at high risk of leak, despite efforts to improve tissue viability, would likely be better served by a permanent ostomy instead of a failed, painful attempt at a restorative procedure. Postulated mechanisms for the increased incidence of leak afterresection of rectal cancer can each contribute to inadequate oxygen delivery to the healing anastomosis; each of which are present at the time of surgery. The Stapled Anastomosis Viability Evaluation (SAVE) System integrates into the surgical workflow by replacing the anvil of commercially available, circular staplers with a sensing anvil. The SAVE Anvil uses an array of multi-modality sensors to enable the surgeon to perform the procedure in a standardized manner while assessing the viability of the anastomosis at the staple line throughout its formation. Sensor data is transmitted to a base station where actionable information is displayed to the surgical team. Phase I demonstrated the feasibility of measuring interstitial oxygenation levels at the anastomotic site using oxygen dependent quenching of phosphorescence via a locally injected phosphor. Initial toxicity studies of the probe indicate non-toxicity at dose-response levels. Phase II of this study will establish the relationship between interstitialoxygen level and integrity of the anastomosis through survival studies in animal models. Concurrently the candidate phosphor with undergo requisite screening, and pharmacokinetic evaluation in preparation for pre-IND discussion. PUBLIC HEALTH RELEVANCE: Colorectal cancer afflicts 1.2 million people annually, the mainstay of treatment being surgical removal of the afflicted segment of bowel. After the surgical procedure the intestine fails to heal in as many as 14% of patients resulting in life threatening illness as fecal material contaminates the abdominal cavity. Surgisense's Stapled Anastomosis Viability Evaluation (SAVE) System strives to reduce the occurrence of this complication as the first, clinically relevant, intra-operative device capableof providing real-tie assessment of an intestinal tissue's ability to heal; reducing patient suffering, while saving 2 billion dollars annually in excess healthcare costs.

Principal Investigator:

Jason M. Zand
202-777-3626
jzand@surgisense.com

Business Contact:

Jason M. Xand
202-777-3626
jzand@surgisense.com
Small Business Information at Submission:

SURGISENSE CORPORATION
5272 River Road Suite 200 Bethesda, MD -

EIN/Tax ID: 142170105
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No